TheraRadar
← Back
Data updated: Jun 28, 2026

ALKEM LABS LTD

Generics

ALKEM LABS LTD is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease.

1985
Since
128
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
1 Small Molecules

ALKEM LABS LTD's Key Drugs

ALKEM LABS LTD's core commercial portfolio centers on CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE, AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

ALKEM LABS LTD's Therapeutic Areas

ALKEM LABS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 31%
15 drugs
Neurology 29%
14 drugs
Infectious Disease 17%
8 drugs
Immunology 13%
6 drugs
Respiratory 10%
5 drugs

ALKEM LABS LTD Pipeline Snapshot

Active clinical trials for ALKEM LABS LTD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE leads revenue
  • 5 key drugs tracked

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling